M1 Kliniken AG (DE:M12)
XETRA:M12
Want to see DE:M12 full AI Analyst Report?
Top Page
M1 Kliniken AG
(XETRA:M12)
Select Model
Select Model
Rating:80Outperform
Price Target:
€19.00
▲(4.63% Upside)
Action:Reiterated
Date:11/26/25
M1 Kliniken AG earns an overall score of 80, driven primarily by strong financial performance (score: 83, weight: 0.5) with robust revenue and cash flow growth. Positive technical momentum (score: 78, weight: 0.3) further supports the outlook, though valuation (score: 70, weight: 0.2) remains average. The score reflects a solid investment with minor concerns around margin improvement and potential technical pullbacks.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong demand for services and effective market expansion, supporting long-term business sustainability.
Negative Factors
Decreased Total Assets
Declining total assets may signal potential asset divestment or underinvestment, which could impact future growth and operational capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong demand for services and effective market expansion, supporting long-term business sustainability.
Read all positive factors
M1 Kliniken AG (M12) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€362.35M
Dividend Yield2.8%
Average Volume (3M)13.86K
Price to Earnings (P/E)6.1
Beta (1Y)0.31
Revenue Growth6.52%
EPS Growth7.17%
CountryDE
Employees219
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.96
Shares Outstanding19,643,402
10 Day Avg. Volume17,849
30 Day Avg. Volume13,861
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.90
Price to Sales (P/S)0.91
P/FCF Ratio10.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.09
Revenue Forecast (FY)€370.88M
M1 Kliniken AG Business Overview & Revenue Model
Company Description
M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty ...
How the Company Makes Money
M1 Kliniken AG generates revenue primarily through the provision of aesthetic medical services, including surgical and non-surgical treatments. Key revenue streams include fees for cosmetic procedures, consultations, and follow-up care. The compan...
M1 Kliniken AG Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
75
Positive
Cash Flow
88
Very Positive
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 354.98M | 339.18M | 316.32M | 285.29M | 314.61M | 159.59M |
| Gross Profit | 42.64M | 63.60M | 32.47M | 21.72M | 26.06M | 13.61M |
| EBITDA | 35.21M | 33.44M | 21.79M | 16.07M | 19.78M | 10.59M |
| Net Income | 17.74M | 16.02M | 10.27M | 4.32M | 8.91M | 6.82M |
Balance Sheet | ||||||
| Total Assets | 203.28M | 187.87M | 212.95M | 197.02M | 198.11M | 188.74M |
| Cash, Cash Equivalents and Short-Term Investments | 45.67M | 23.69M | 22.76M | 47.50M | 49.12M | 34.14M |
| Total Debt | 21.82M | 10.42M | 17.04M | 19.67M | 30.93M | 39.09M |
| Total Liabilities | 56.26M | 53.65M | 69.73M | 53.97M | 58.21M | 73.42M |
| Stockholders Equity | 118.00M | 106.10M | 113.25M | 95.52M | 95.03M | 85.75M |
Cash Flow | ||||||
| Free Cash Flow | 34.46M | 29.55M | 6.80M | 19.25M | 14.32M | 7.93M |
| Operating Cash Flow | 34.70M | 30.55M | 7.81M | 21.02M | 15.66M | 9.38M |
| Investing Cash Flow | 5.74M | -5.67M | -9.36M | -1.77M | 213.19K | 3.12M |
| Financing Cash Flow | -14.32M | -30.44M | -14.81M | -21.97M | 4.03M | 377.65K |
M1 Kliniken AG Technical Analysis
Positive
18.16
Price Trends
15.84
Positive
16.56
Positive
15.76
Positive
Market Momentum
0.84
Negative
66.38
Neutral
82.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Positive. The current price of 18.16 is above the 20-day moving average (MA) of 17.13, above the 50-day MA of 15.84, and above the 200-day MA of 15.76, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 66.38 is Neutral, neither overbought nor oversold. The STOCH value of 82.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:M12.
M1 Kliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €362.35M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
74 Outperform | €151.50M | 18.52 | 22.77% | ― | 33.49% | 81.79% | |
70 Outperform | €92.48M | 3.21 | 12.13% | 5.31% | 5742.69% | -8.56% | |
64 Neutral | €169.10M | 116.46 | 10.71% | 1.12% | 5.13% | 11.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | €20.76M | -1.54 | 23.56% | ― | 3.51% | -5.66% |
* Healthcare Sector Average
DE:M12
M1 Kliniken AG
18.76
5.01
36.44%
DE:MED
MEDICLIN
3.52
0.62
21.38%
DE:MAK
MATERNUS-Kliniken AG
1.01
-0.57
-36.04%
DE:LIK
Limes Schlosskliniken AG
505.00
205.00
68.33%
DE:HAEK
HAEMATO AG
11.70
-0.75
-6.04%
DE:93M1
MPH Health Care AG
25.90
2.04
8.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.